Search ClinicalTrials.gov studies by condition, drug or sponsor and get status, phase, locations, dates and enrollment as clean JSON.
Run in Postman
{
"tool": "clinical-trials",
"count": 20,
"results": [
{
"query": "semaglutide",
"nctId": "NCT07295223",
"title": "Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)",
"officialTitle": "GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot Study",
"status": "COMPLETED",
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL",
"conditions": [
"Acute Myocardial Infarction With ST Elevation"
],
"interventions": [
"DRUG: Dapagliflozin 10 MG Oral Tablet",
"DRUG: Semaglutide (Rybelsus®)"
],
"sponsor": "Instituto Mexicano del Seguro Social",
"sponsorClass": "OTHER_GOV",
"enrollment": 44,
"startDate": "2025-12-30",
"primaryCompletionDate": "2026-10-30",
"lastUpdated": "2026-11-04",
"hasResults": false,
"locationCount": 1,
"countries": [
"Mexico"
],
"sampleLocations": [
"Hospital de Especialidades No.1, Centro Médico Nacional del Bajío, León, Guanajuato, Mexico"
],
"briefSummary": "The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition. It has now been proven that inflammation is key in the development of complications after an acute myocardial infarction. These complications can be immediate and mechanical, such as ventricular wall rupture and ventricular arrhythmia, or long-term, presenting as major cardiovascular events like heart failure.\n\nDuring acute myocardial infarction (AMI), circulating high-sensitivity CRP levels increase approximately 6 hours after the onset of ischemia. CRP levels measured between 24 and 72 hours after symptom onset are a significant prognostic marker for one-year outcomes. Higher high-sensitivity CRP levels at the time of AMI are linked to more severe coronary atherosclerotic lesions seen on angiography and lower LVEF one month after the event. A serum high-sensitivity CRP concentration greater than 10 mg/L after an AMI indicates inflammation, reflecting myocardial necrosis, plaque rupture, and acute thrombosis. In patients with AMI, persistent or increasing CRP levels are strongly associated with a higher risk of all-cause and non-cardiovascular death, especially when inflammation (CRP \\> 2.0 mg/L) continues for a year.\n\nAside from reperfusion therapy, very few pharmacological approaches have been used to reduce inflammation after AMI. One such approach was the use of colchicine in the COVERT-MI randomized, doubl",
"url": "https://clinicaltrials.gov/study/NCT07295223"
},
{
"query": "semaglutide",
"nctId": "NCT07772960",
"title": "Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes",
"officialTitle": "Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes",
"status": "RECRUITING",
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL",
"conditions": [
"Alcohol Use Disorder (AUD)",
"Obesity (BMI Equal to or >30)"
],
"interventions": [
"OTHER: Placebo",
"DRUG: Semaglutide 1.0 mg",
"DRUG: Semaglutide 2.0 mg"
],
"sponsor": "Yale University",
"sponsorClass": "OTHER",
"enrollment": 90,
"startDate": "2026-10-01",
"primaryCompletionDate": "2031-10-31",
"lastUpdated": "2026-11-04",
"hasResults": false,
"locationCount": 2,
"countries": [
"United States"
],
"sampleLocations": [
"Yale Stress Center, New Haven, Connecticut, United States",
"Yale Stress Center, New Haven, Connecticut, United States"
],
"briefSummary": "This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.",
"url": "https://clinicaltrials.gov/study/NCT07772960"
},
{
"query": "semaglutide",
"nctId": "NCT06975111",
"title": "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",
"officialTitle": "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",
"status": "RECRUITING",
"phases": [
"PHASE2",
"PHASE3"
],
"studyType": "INTERVENTIONAL",
"conditions": [
"Menopause",
"Menopause Hot Flashes",
"Menopause Related Conditions",
"Cardiovascular"
],
"interventions": [
"DRUG: Metformin",
"DRUG: semaglutide",
"DRUG: Anti-hypertensives",
"DRUG: Lipid Lowering Medication",
"BEHAVIORAL: Life style intervention",
"DRUG: Fezolinetant",
"DRUG: Hormonal therapy"
],
"sponsor": "University of Colorado, Denver",
"sponsorClass": "OTHER",
"enrollment": 200,
"startDate": "2026-03-01",
"primaryCompletionDate": "2029-10-31",
"lastUpdated": "2026-11-04",
"hasResults": false,
"locationCount": 3,
"countries": [
"United States"
],
"sampleLocations": [
"University of Colorado-School of Medicine, Aurora, Colorado, United States",
"University of North Carolina, School of Medicine, Chapel Hill, North Carolina, United States",
"Virginia Commonwealth University, Richmond, Virginia, United States"
],
"briefSummary": "What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.",
"url": "https://clinicaltrials.gov/study/NCT06975111"
},
{
"query": "semaglutide",
"nctId": "NCT06897475",
"title": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide",
"officialTitle": "A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal",
"status": "RECRUITING",
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL",
"conditions": [
"Type 2 Diabetes"
],
"interventions": [
"DRUG: LY3457263",
"DRUG: Placebo"
],
"sponsor": "Eli Lilly and Company",
"sponsorClass": "INDUSTRY",
"enrollment": 200,
"startDate": "2025-03-28",
"primaryCompletionDate": "2027-05",
"lastUpdated": "2026-11-04",
"hasResults": false,
"locationCount": 60,
"countries": [
"United States",
"Canada",
"Germany",
"Poland",
"Puerto Rico",
"United Kingdom"
],
"sampleLocations": [
"Helios Clinical Research - Phoenix, Phoenix, Arizona, United States",
"Wolverine Clinical Trials, Santa Ana, California, United States",
"Renstar Medical Research, Ocala, Florida, United States",
"Oviedo Medical Research, Oviedo, Florida, United States",
"Balanced Life Health Care Solutions/SKYCRNG, Lawrenceville, Georgia, United States"
],
"briefSummary": "The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.",
"url": "https://clinicaltrials.gov/study/NCT06897475"
},
{
"query": "semaglutide",
"nctId": "NCT07832084"
}
],
"_note": "Response truncated for documentation purposes"
}
curl --location --request GET 'https://zylalabs.com/api/14726/clinical+trials+search+api/38085/clinical+trials+search?items=semaglutide' --header 'Authorization: Bearer YOUR_API_KEY'
After signing up, every developer is assigned a personal API access key, a unique combination of letters and digits provided to access to our API endpoint. To authenticate with the Clinical Trials Search API simply include your bearer token in the Authorization header.
| Header | Description |
|---|---|
Authorization
|
Required
Should be Bearer access_key. See "Your API Access Key" above when you are subscribed.
|
No long-term commitment. Upgrade, downgrade, or cancel anytime.
Search ClinicalTrials.gov studies by condition, drug or sponsor and get status, phase, locations, dates and enrollment as clean JSON.
Send the items query parameter with up to 5 values (comma-separated), for example items=semaglutide. Optional parameters: conditions, statuses, location, maxResultsPerQuery.
JSON with tool, count and a results array. Each result row has the same fields as the example response on this page.
One call counts as one request, even when it asks for up to 5 queries at once. Asking for more options or a higher limit in the same call still counts as one request.
Official public APIs, public web pages, public files and DNS, fetched live at request time. No logins or paywalls are bypassed.
Most calls return in 2 to 15 s. Past 80 s you get HTTP 503 with Retry-After; send fewer items and retry.
Optional query parameters: conditions, statuses, location, maxResultsPerQuery. Each is listed under Parameters on this page with its allowed values or range. Values outside those limits return HTTP 400 with the allowed range.
JSON with an error message: 400 for a missing or invalid parameter (with the allowed values), 422 when no item can be processed (with a reason for each), 429 over the rate limit, and 503 with Retry-After when busy or past 80 s. If only some items fail, you get 200 with rows for the items that worked.
To obtain your API key, first sign in to your account and navigate to the API you want to use. From the API's Pricing section, choose a plan and complete the subscription process. Once subscribed, return to the API page and you will see your API Access Key displayed at the top of the documentation page. You can use this key to authenticate your requests.
You can’t switch APIs during the free trial. If you subscribe to a different API, your trial will end and the new subscription will start as a paid plan.
The free trial lasts for 7 days and allows you to make up to 50 API requests.
No, the free trial is available only once, so we recommend using it on the API that interests you the most. Most of our APIs offer a free trial, but some may not include this option.
Yes. If the API offers a free trial, you will see a "Free 7-Day Trial" option in its Pricing section. The trial lasts for 7 days and allows up to 50 API requests, enabling you to evaluate the API before subscribing to a paid plan.
Zyla API Hub is like a big store for APIs, where you can find thousands of them all in one place. We also offer dedicated support and real-time monitoring of all APIs. Once you sign up, you can pick and choose which APIs you want to use. Just remember, each API needs its own subscription. But if you subscribe to multiple ones, you'll use the same key for all of them, making things easier for you.
You can monitor your API usage through the response headers included with every request:
x-zyla-api-calls-monthly-used: Shows the total number of API requests you have used during the current billing period.
x-zyla-api-calls-monthly-remaining: Shows the number of API requests you have remaining for the current billing period.
Yes, you can cancel your subscription at any time. Simply go to the Pricing section of the API you're subscribed to and click the "Unsubscribe" button.
Please note that upgrades, downgrades, and cancellations take effect immediately. Once your subscription is canceled, access to the service will end immediately, regardless of any remaining API calls in your quota.
Please have a look at our Refund Policy: https://zylalabs.com/terms#refund
